Education
About Us
Working with TipRanks
Follow Us
Organogenesis Holdings (ORGO)
NASDAQ:ORGO
Total Valuation
Organogenesis Holdings has a market cap or net worth of $331.89M. The enterprise value is $371.06M.
Market Cap$331.89M
Enterprise Value$371.06M
Share Statistics
Organogenesis Holdings has 128,640,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding128,640,670
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Organogenesis Holdings’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 8.59%.
Return on Equity (ROE)0.09
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)8.59%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee649.22K
Profits Per Employee42.61K
Employee Count869
Asset Turnover0.94
Inventory Turnover5.03
Valuation Ratios
The current PE Ratio of Organogenesis Holdings is 3.8. Organogenesis Holdings’s PEG ratio is -0.00753.
PE Ratio3.8
PS Ratio1.16
PB Ratio1.51
Price to Fair Value1.51
Price to FCF-26.84
Price to Operating Cash Flow-31.76
PEG Ratio-0.00753
Income Statement
In the last 12 months, Organogenesis Holdings had revenue of 564.17M and earned 37.03M in profits. Earnings per share was 0.16.
Revenue564.17M
Gross Profit415.06M
Operating Income56.38M
Pretax Income46.97M
Net Income37.03M
EBITDA83.32M
Earnings Per Share (EPS)0.16
Cash Flow
In the last 12 months, operating cash flow was -10.31M and capital expenditures -14.15M, giving a free cash flow of -24.46M billion.
Operating Cash Flow-10.31M
Free Cash Flow-24.46M
Free Cash Flow per Share-0.19
Dividends & Yields
Organogenesis Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.54
52-Week Price Change-48.09%
50-Day Moving Average3.75
200-Day Moving Average4.32
Relative Strength Index (RSI)22.41
Average Volume (3m)675.09K
Important Dates
Organogenesis Holdings upcoming earnings date is May 7, 2026, After Close (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Organogenesis Holdings as a current ratio of 3.62, with Debt / Equity ratio of 30.62%
Current Ratio3.62
Quick Ratio3.32
Debt to Market Cap0.11
Net Debt to EBITDA0.47
Interest Coverage Ratio24.72
Taxes
In the past 12 months, Organogenesis Holdings has paid 9.94M in taxes.
Income Tax9.94M
Effective Tax Rate0.21
Enterprise Valuation
Organogenesis Holdings EV to EBITDA ratio is 8.35, with an EV/FCF ratio of -28.44.
EV to Sales1.23
EV to EBITDA8.35
EV to Free Cash Flow-28.44
EV to Operating Cash Flow-67.48
Balance Sheet
Organogenesis Holdings has $93.68M in cash and marketable securities with $132.84M in debt, giving a net cash position of -$39.16M billion.
Cash & Marketable Securities$93.68M
Total Debt$132.84M
Net Cash-$39.16M
Net Cash Per Share-$0.30
Tangible Book Value Per Share$3.12
Margins
Gross margin is 75.68%, with operating margin of 9.99%, and net profit margin of 6.56%.
Gross Margin75.68%
Operating Margin9.99%
Pretax Margin8.33%
Net Profit Margin6.56%
EBITDA Margin14.77%
EBIT Margin9.99%
Analyst Forecast
The average price target for Organogenesis Holdings is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.00
Price Target Upside96.08% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast2.24%
EPS Growth Forecast-67.56%